-
1
-
-
79952613370
-
Systematic review of medical treatment in melanoma: Current status and future prospects
-
Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16:5-24.
-
(2011)
Oncologist
, vol.16
, pp. 5-24
-
-
Garbe, C.1
Eigentler, T.K.2
Keilholz, U.3
-
2
-
-
0029086370
-
Prognostic factors in 1, 521 melanoma patients with distant metastases
-
Barth A, Wanek LA, Morton DL. Prognostic factors in 1, 521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193-201.
-
(1995)
J Am Coll Surg
, vol.181
, pp. 193-201
-
-
Barth, A.1
Wanek, L.A.2
Morton, D.L.3
-
3
-
-
84874605864
-
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
-
Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Onc. 2013;31:616-622.
-
(2013)
J Clin Onc
, vol.31
, pp. 616-622
-
-
Ribas, A.1
Kefford, R.2
Marshall, M.A.3
-
4
-
-
69949095926
-
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma
-
Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591-5598.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5591-5598
-
-
Weber, J.1
Thompson, J.A.2
Hamid, O.3
-
5
-
-
61449090474
-
Phase I/II trial of tremelimumab in patients with metastatic melanoma
-
Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Onc. 2009;27:1075-1081.
-
(2009)
J Clin Onc
, vol.27
, pp. 1075-1081
-
-
Camacho, L.H.1
Antonia, S.2
Sosman, J.3
-
6
-
-
75249100054
-
Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study
-
Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155-164.
-
(2010)
Lancet Oncol
, vol.11
, pp. 155-164
-
-
Wolchok, J.D.1
Neyns, B.2
Linette, G.3
-
7
-
-
33846465547
-
Immunostimulatory monoclonal antibodies for cancer therapy
-
Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95-106.
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 95-106
-
-
Melero, I.1
Hervas-Stubbs, S.2
Glennie, M.3
-
9
-
-
42649125225
-
PD-1 and its ligands in tolerance and immunity
-
Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
-
(2008)
Annu Rev Immunol
, vol.26
, pp. 677-704
-
-
Keir, M.E.1
Butte, M.J.2
Freeman, G.J.3
-
10
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
-
(2012)
Nat Rev Cancer
, vol.12
, pp. 252-264
-
-
Pardoll, D.M.1
-
11
-
-
68149155982
-
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
-
Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206:1717-1725.
-
(2009)
J Exp Med
, vol.206
, pp. 1717-1725
-
-
Peggs, K.S.1
Quezada, S.A.2
Chambers, C.A.3
-
12
-
-
84898973055
-
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
-
Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020-1030.
-
(2014)
J Clin Oncol
, vol.32
, pp. 1020-1030
-
-
Topalian, S.L.1
Sznol, M.2
McDermott, D.F.3
-
13
-
-
84931083080
-
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial
-
Weber JS, D?Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375-384.
-
(2015)
Lancet Oncol
, vol.16
, pp. 375-384
-
-
Weber, J.S.1
Dangelo, S.P.2
Minor, D.3
-
14
-
-
84971619894
-
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial
-
Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976-983.
-
(2016)
Lancet Oncol
, vol.17
, pp. 976-983
-
-
Goldberg, S.B.1
Gettinger, S.N.2
Mahajan, A.3
-
15
-
-
85033400433
-
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
-
Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824-1835.
-
(2017)
N Engl J Med
, vol.377
, pp. 1824-1835
-
-
Weber, J.1
Mandala, M.2
Del Vecchio, M.3
-
16
-
-
84929481481
-
Pembrolizumab versus ipilimumab in advanced melanoma
-
Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372: 2521-2532.
-
(2015)
N Engl J Med
, vol.372
, pp. 2521-2532
-
-
Robert, C.1
Schachter, J.2
Long, G.V.3
-
17
-
-
78449244037
-
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications
-
Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010;37:499-507.
-
(2010)
Semin Oncol
, vol.37
, pp. 499-507
-
-
Di Giacomo, A.M.1
Biagioli, M.2
Maio, M.3
-
18
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-2526.
-
(2011)
N Engl J Med
, vol.364
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
-
19
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O?Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
Oday, S.J.2
McDermott, D.F.3
-
20
-
-
69149107165
-
Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement
-
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269.
-
(2009)
Ann Intern Med
, vol.151
, pp. 264-269
-
-
Moher, D.1
Liberati, A.2
Tetzlaff, J.3
-
22
-
-
36849093844
-
Patient-reported outcomes and the evolution of adverse event reporting in oncology
-
Trotti A, Colevas AD, Setser A, et al. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25:5121-5127.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5121-5127
-
-
Trotti, A.1
Colevas, A.D.2
Setser, A.3
-
23
-
-
84863847959
-
Closing the gap between methodologists and end-users: R as computational back-end
-
Wallace BC, Dahabreh IJ, Trikalinos TA, et al. Closing the gap between methodologists and end-users: R as computational back-end. J Stat Softw. 2012;49:5.
-
(2012)
J Stat Softw
, vol.49
, pp. 5
-
-
Wallace, B.C.1
Dahabreh, I.J.2
Trikalinos, T.A.3
-
24
-
-
84863796659
-
-
Review Manager (RevMan) [Computer Program] Version 53. Copenhagen: The Nordic Cochrane Centre
-
Review Manager (RevMan) [Computer Program], Version 53. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014. Available at: http://community.cochrane. org/tools/review-production-tools/revman-5/about-revman-5.
-
(2014)
The Cochrane Collaboration
-
-
-
26
-
-
84994874924
-
Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy
-
Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845-1855.
-
(2016)
N Engl J Med
, vol.375
, pp. 1845-1855
-
-
Amm, E.1
Chiarion-Sileni, V.2
Grob, J.-J.3
-
27
-
-
84860446616
-
Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial
-
Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459-465.
-
(2012)
Lancet Oncol
, vol.13
, pp. 459-465
-
-
Margolin, K.1
Ernstoff, M.S.2
Hamid, O.3
-
28
-
-
84929481482
-
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
-
Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-2017.
-
(2015)
N Engl J Med
, vol.372
, pp. 2006-2017
-
-
Postow, M.A.1
Chesney, J.2
Pavlick, A.C.3
-
29
-
-
84925222119
-
Nivolumab in previously untreated melanoma without BRAF mutation
-
Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-330.
-
(2015)
N Engl J Med
, vol.372
, pp. 320-330
-
-
Robert, C.1
Long, G.V.2
Brady, B.3
-
30
-
-
84991110530
-
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): An openlabel, randomised, phase 2 trial
-
Weber JS, Gibney G, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an openlabel, randomised, phase 2 trial. Lancet Oncol. 2016;17:943-955.
-
(2016)
Lancet Oncol
, vol.17
, pp. 943-955
-
-
Weber, J.S.1
Gibney, G.2
Sullivan, R.J.3
-
31
-
-
85044389420
-
Open-label, multicenter, single-Arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
-
Zimmer L, Eigentler TK, Kiecker F, et al. Open-label, multicenter, single-Arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. J Transl Med. 2015;5:1-11.
-
(2015)
J Transl Med
, vol.5
, pp. 1-11
-
-
Zimmer, L.1
Eigentler, T.K.2
Kiecker, F.3
-
32
-
-
84938205998
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial
-
Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908-918.
-
(2015)
Lancet Oncol
, vol.16
, pp. 908-918
-
-
Ribas, A.1
Puzanov, I.2
Dummer, R.3
-
33
-
-
84936147067
-
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.
-
(2015)
N Engl J Med
, vol.373
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
-
34
-
-
76049092889
-
Phase II trial of tremelimumab (CP-675 206) in patients with advanced refractory or relapsed melanoma
-
Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675, 206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res. 2010;16:1042-1048.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1042-1048
-
-
Kirkwood, J.M.1
Lorigan, P.2
Hersey, P.3
-
35
-
-
84879045360
-
Randomized phase i pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma
-
Weber J, Hamid O, Amin A, et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun. 2013;13:7.
-
(2013)
Cancer Immun
, vol.13
, pp. 7
-
-
Weber, J.1
Hamid, O.2
Amin, A.3
-
36
-
-
85014741205
-
Phase 1b study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041
-
Yamazaki N, Takenouchi T, Fujimoto M, et al. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemother Pharmacol. 2017;79:651-660.
-
(2017)
Cancer Chemother Pharmacol
, vol.79
, pp. 651-660
-
-
Yamazaki, N.1
Takenouchi, T.2
Fujimoto, M.3
-
37
-
-
85016813132
-
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial
-
Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18:611-622.
-
(2017)
Lancet Oncol
, vol.18
, pp. 611-622
-
-
Ascierto, P.A.1
Del Vecchio, M.2
Robert, C.3
-
38
-
-
85005950533
-
Immunotherapy in melanoma: Recent advances and future directions
-
Franklin C, Livingstone E, Roesch A, et al. Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol. 2017;43:604-611.
-
(2017)
Eur J Surg Oncol
, vol.43
, pp. 604-611
-
-
Franklin, C.1
Livingstone, E.2
Roesch, A.3
-
39
-
-
33744792341
-
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyteassociated antigen 4
-
Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyteassociated antigen 4. J Clin Oncol. 2006;24:2283-2289.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2283-2289
-
-
Beck, K.E.1
Blansfield, J.A.2
Tran, K.Q.3
-
40
-
-
84864052441
-
Management of immunerelated adverse events and kinetics of response with ipilimumab
-
Weber JS, Kahler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-2697.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2691-2697
-
-
Weber, J.S.1
Kahler, K.C.2
Hauschild, A.3
-
42
-
-
84964355523
-
Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology
-
Colt DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14:450-473.
-
(2016)
J Natl Compr Canc Netw
, vol.14
, pp. 450-473
-
-
Colt, D.G.1
Thompson, J.A.2
Algazi, A.3
-
43
-
-
0028867420
-
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
-
Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541-547.
-
(1995)
Immunity
, vol.3
, pp. 541-547
-
-
Tivol, E.A.1
Borriello, F.2
Schweitzer, A.N.3
-
44
-
-
84879477789
-
Ipilimumab and its toxicities: A multidisciplinary approach
-
Fecher LA, Agarwala SS, Hodi FS, et al. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013;18: 733-743.
-
(2013)
Oncologist
, vol.18
, pp. 733-743
-
-
Fecher, L.A.1
Agarwala, S.S.2
Hodi, F.S.3
-
45
-
-
34547214205
-
Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans
-
Roncarolo M-G, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol. 2007;7:585-598.
-
(2007)
Nat Rev Immunol
, vol.7
, pp. 585-598
-
-
Roncarolo, M.-G.1
Battaglia, M.2
-
46
-
-
84863987094
-
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: A mechanistic explanation for ipilimumab-induced severe enterocolitis?
-
Nancey S, Boschetti G, Cotte E, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis? Inflamm Bowel Dis. 2012;18:E1598-E1600.
-
(2012)
Inflamm Bowel Dis
, vol.18
, pp. E1598-E1600
-
-
Nancey, S.1
Boschetti, G.2
Cotte, E.3
-
47
-
-
84929157234
-
Anti-PD-1 therapy in melanoma
-
Homet Moreno B, Parisi G, et al. Anti-PD-1 therapy in melanoma. Semin Oncol. 2015;42:466-473.
-
(2015)
Semin Oncol
, vol.42
, pp. 466-473
-
-
Homet Moreno, B.1
Parisi, G.2
-
48
-
-
84957547203
-
Ipilimumab-induced gastrointestinal toxicities: A management algorithm
-
Klair JS, Girotra M, Hutchins LF, et al. Ipilimumab-induced gastrointestinal toxicities: a management algorithm. Dig Dis Sci. 2016;61:2132-2139.
-
(2016)
Dig Dis Sci
, vol.61
, pp. 2132-2139
-
-
Klair, J.S.1
Girotra, M.2
Hutchins, L.F.3
-
49
-
-
85006410852
-
Systematic review: Colitis associated with anti-CTLA-4 therapy
-
Gupta A, De Felice KM, Loftus EVJ, et al. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42:406-417.
-
(2015)
Aliment Pharmacol Ther
, vol.42
, pp. 406-417
-
-
Gupta, A.1
De Felice, K.M.2
Loftus, E.V.J.3
-
50
-
-
84936936976
-
Ipilimumab-induced colitis in patients with metastatic melanoma
-
De Felice KM, Gupta A, Rakshit S, et al. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res. 2015;25:321-327.
-
(2015)
Melanoma Res
, vol.25
, pp. 321-327
-
-
De Felice, K.M.1
Gupta, A.2
Rakshit, S.3
-
51
-
-
84963860995
-
Clinical, endoscopic, and histologic characteristics of ipilimumab-Associated colitis
-
Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-Associated colitis. Clin Gastroenterol Hepatol. 2016;14:836-842.
-
(2016)
Clin Gastroenterol Hepatol
, vol.14
, pp. 836-842
-
-
Verschuren, E.C.1
Van Den Eertwegh, A.J.2
Wonders, J.3
-
52
-
-
84877038380
-
Ipilimumab-induced acute severe colitis treated by infliximab
-
Pages C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23: 227-230.
-
(2013)
Melanoma Res
, vol.23
, pp. 227-230
-
-
Pages, C.1
Gornet, J.M.2
Monsel, G.3
|